metric reductions of aryl ketones,5 imines,6 enones,7 R,â-
unsaturated esters,8 nitroalkenes,9 and R,â-unsaturated ni-
triles.10 We envisioned that an asymmetric conjugate reduction
of 3,3-diaryl-substituted acrylonitriles via copper hydride
catalysis would be an unique and attractive route to 3,3-
diarylpropionitriles and thus to 3,3-diarylpropylamines. Since
the nitrile group prefers end-on coordination to a metal, most
asymmetric hydrogenation catalysts are not generally com-
petent. One report has been recently made on the enantio-
selective reduction of 3-aryl-3-pyridyl-R,â-unsaturated ni-
triles catalyzed by Ru-phosphine complexes.4c However,
only substrates with a suitable secondary coordinating atom
were reactive under high hydrogen pressure. In this reprot,
we describe a copper-catalyzed enantioselective conjugate
reduction of 3,3-diarylacrylonitriles that efficiently occurs
with high levels of enantioselectivity. The substrate scope
of this reaction includes 3,3-diaryl-substituted unsaturated
substrates having no secondary coordinating functional
groups and this is, to the best of our knowledge, the first
example of the enantioselective reduction of such com-
pounds.
Figure 1. Structures of pheniramines and arpromidine.
product 2a of very high ee (96% ee; Table 1, entry 1).
Reductions with Mandyphos ((R)-(S)-4; entry 5) and Wal-
phos-type ligand ((R)-(S)-5; entry 6) were very slow,
Table 1. Asymmetric Conjugate Reduction of (E)-1a with
We prepared (E)-3-phenyl-3-(pyridin-2-yl)acrylonitrile
(1a) as the starting material. The aryl(pyridyl)propionitriles
resulting from this type of substrate constitute a characteristic
feature of H1 antihistaminic agents, pheniramines,11 and the
potent histamine H2 agonist, arpromidine and its analogues
(Figure 1).12 In initial studies on the reduction of (E)-1a with
3 mol % of Cu(OAc)2 in the presence of excess PMHS, we
screened various chiral ligands (Table 1). To our delight,
with Josiphos-type ligands (3a-d),13 the reaction proceeded
Various Ligands
temp
(°C)
concn
(M)
time
(h)
yield
(%)
ee
entry
ligand
(%)a
1
2
3
4
5
6
7
8b
9
3a (Josiphos)
0
0
0
0
0
0
0
rt
0
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
1
17
12
24
24
60
60
24
4
90
70
70
78
66
87
70
86
91
96
86
65
53
18
94
37
92
95
3b
3c
3d
4
5
6
3a
3a
17
a Determined by chiral HPLC. b rt ) ∼ 22 °C.
although the latter ligand gave good enantioselectivity. The
C2-symmetric (R)-Ph-MeOBiphep ligand (6; entry 7) showed
poor enantioselectivity. We chose Josiphos as the chiral
ligand for further investigation. Increasing reaction temper-
ature to room temperature resulted in a small drop in ee (entry
8) with an increase of reaction rate, and conducting the
reduction of 1a at a higher substrate concentration had no
significant effect on the enantioselectivity (entry 9).
Next, we examined the asymmetric reductions of several
substrates by employing a catalytic amount of Cu(OAc)2 and
3a in toluene in the presence of PMHS and t-BuOH (Table
2). In general, most of the reactions proceeded to completion
within 1-4 h at room temperature to furnish diaryl products
in good ee and yields. Both (E)- and (Z)-isomers (1d, 1e,
and 1g) were reduced smoothly, affording the product in the
opposite configuration.14
smoothly to yield the desired product (entries 1-4). In
particular, the Josiphos ligand (3a) afforded the reduced
(5) (a) Lipshutz, B. H.; Noson, K.; Chrisman, W. J. Am. Chem. Soc.
2001, 123, 12917. (b) Lee, D.; Yun, J. Tetrahedron Lett. 2004, 45, 5415.
(6) Lipshutz, B. H.; Shimizu, H. Angew. Chem., Int. Ed. 2004, 43, 2228.
(7) (a) Moritani, Y.; Appella, D. H.; Jurkauskas, V.; Buchwald, S. L. J.
Am. Chem. Soc. 2000, 122, 6797. (b) Lipshutz, B. H.; Servesko, J. M.
Angew. Chem., Int. Ed. 2003, 42, 4789.
(8) (a) Appella, D. H.; Moritani, Y.; Shintani, R.; Ferreira, E. M.;
Buchwald, S. L. J. Am. Chem. Soc. 1999, 121, 9473. (b) Lipshutz, B. H.;
Servesko, J. M.; Taft, B. R. J. Am. Chem. Soc. 2004, 126, 8352.
(9) Czekelius, C.; Carreira, E. M. Angew. Chem., Int. Ed. 2003, 42, 4793.
(10) Lee, D.; Kim, D.; Yun, J. Angew. Chem., Int. Ed. 2006, 45, 2785.
(11) (a) Anthes, J. C.; Gilchrest, H.; Richard, C.; Eckel, S.; Hesk, D.;
West, R. E.; Williams, S. M.; Greenfeder, S.; Billah, M.; Kreutner, W.;
Egan, R. W. Eur. J. Pharmacol. 2002, 449, 229. (b) Botteghi, C.; Chelucci,
G.; Ponte, G. D.; Marchetti, M.; Paganelli, S. J. Org. Chem. 1994, 59, 7125
and references cited therein.
(12) (a) Dove, S.; Elz, S.; Seifert, R.; Buschauer, A. Mini-ReV. Med.
Chem. 2004, 4, 941. (b) Buschauer, A. J. Med. Chem. 1989, 32, 1963. (c)
Buschauer, A.; Friese-Kimmel, A.; Baumann, G.; Schunack, W. Eur. J.
Med. Chem. 1992, 27, 321.
(13) For a review of Josiphos ligands, see: Blaser, H.-U.; Brieden, W.;
Pugin, B.; Spindler, F.; Studer, M.; Togni, A. Top. Catal. 2002, 19, 3.
2750
Org. Lett., Vol. 9, No. 14, 2007